CClinicalTrials.gg
CompletedNCT03302871Updated Apr 24, 2020

Integrated Management Enhances Functional Gains in Children With Cerebral Palsy Treated by BoNT-A

A Phase 3 interventional study of Botulinum toxin type A and transcranial direct current stimulation in Cerebral Palsy, sponsored by Kocaeli University. Completed at 1 site in Turkey. Open to participants aged 5 Years to 16 Years. Per ClinicalTrials.gov, last updated 2020-04-24.

Sponsored by Kocaeli University · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
5 Years to 16 Years
Sex
All
01

Study summary

Evidence from literature support the use of Botulinum toxin A (BoNT-A) for upper limb spasticity management in children with cerebral palsy (CP). Constraint Induced Movement Therapy (CIMT) and Bilateral Intensive Training (BIT) are indicated as effective and complimentary treatments to improve motor function in these children. In a recent trial combined noninvasiv brain stimulation and CIMT enhanced therapy induced functional gains.

In this clinical trial the aim was to evaluate the effects of transcranial direct current stimulation (t-DCS) plus intensive hybrid training model of modified CIMT and BIT when integrated with BoNT-A treatment in children with unilateral CP.

Read the detailed description

Although BoNT-A is effective in spasticity management there is inconclusive evidence to support its usage for improvement in upper limb activity and function. Combination of BoNT-A and occupational therapy (OT) is found to be more effective then OT alone in reducing impairment, improving activity level and goal achievement. Intensive hybrid training models of CIMT and BIT and noninvasive brain stimulation are promising treatments on motor learning in children with CP. The aim of this clinical trial is to show the additional gains that could be provided by an integrated treatment of transcranial direct current stimulation (t-DCS) plus intensive hybrid training model of modified CIMT and BIT to BoNT-A injections in children with unilateral CP.

02

Conditions studied

  • Cerebral Palsy

Keywords

  • cerebral palsy
  • botulinum toxin A
  • constraint induced movement therapy
  • transcranial direct current stimulation
03

Who can participate

Ages eligible
5 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • diagnosis of unilateral cerebral palsy
  • able to activate wrist and finger extensors
  • being scheduled for BoNT-A treatment for upper limb

Exclusion criteria

Exclusion Criteria:

  • significant loss of wrist and or fingers
  • history of orthopedic surgery to plegic upper limb
04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    İntensive Therapy Group

    Children who received Botulinum toxin type A to plegic upper limb would be treated by transcranial direct current stimulation and a hybrid training model of CIMT and BIT

    Drug: Botulinum toxin type A · Device: transcranial direct current stimulation · Other: hybrid training model of CIMT and BIT

  • Active comparator
    Control Group

    Children who received Botulinum toxin type A to plegic upper limb would continue their usual care

    Drug: Botulinum toxin type A · Other: usual care

Interventions

  • DrugBotulinum toxin type A

    Also known as: Botox, Dysport

  • Devicetranscranial direct current stimulation

    Also known as: noninvasiv brain stimulation

  • Otherhybrid training model of CIMT and BIT
  • Otherusual care

    Also known as: physical therapy

05

What researchers measure

Primary outcomes

  1. Assisting Hand Assesment

    Bilateral Hand Function Evaluation Instrument

    Time frame: 6 weeks

Secondary outcomes

  1. Jebsen Taylor Hand Function Test

    Unilateral Hand Function Evaluation Instrument

    Time frame: 6 weeks

Other outcomes

  1. Modifed Ashworth Scale

    Measurement of Tone

    Time frame: 6 weeks

  2. Active ROM of wrist dorsiflexion

    Measurement of active muscle function

    Time frame: 6 weeks

  3. Modified Tardieu Scale

    Measurement of spasticity

    Time frame: 6 weeks

06

Study locations

1 site
  • Kocaeli University
    Kocaeli, 41050, Turkey
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03302871
Lead sponsor
Kocaeli University
Responsible party
Nigar Dursun (Professor, MD, Kocaeli University) — Principal investigator
First posted
Oct 5, 2017
Start date
Jan 18, 2016
Primary completion
Jan 30, 2020
Completion
Jan 30, 2020
Last update
Apr 24, 2020

Study contacts

Nigar Dursun, MD
principal investigator · Kocaeli University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion